Link:
http://www.positivedetroit.net/2009/11/detroit-medical-center-completes-first.html
Dr. Schmitt of the Detroit Medical Center Completes First Live Tweet of
Birmingham Hip Resurfacing Surgery
Friday, November 27, 2009
On Monday, November 24, the
Detroit Medical Center (DMC) conducted a live surgery simultaneously on
multiple social media platforms. The procedure, called Birmingham Hip
Resurfacing (first of its kind on social media), was performed conducted at DMC
Huron Valley-Sinai Hospital in Commerce Twp., MI.
Dr. Philip Schmitt, D.O., performed the 40-minute surgery, accompanied by a bevy
of healthcare professionals from the DMC Huron Valley-Sinai Hospital staff. Dr.
Schmitt was the first to perform the Birmingham Hip Resurfacing procedure in
Michigan and is considered one nation's best practitioners, having completed
nearly 600 operations to date. This particular procedure is ideal for patients
between the ages of 40 and 60 years old who are active, but suffer from constant
pains from arthritis or joint pain in the hips.
"Birmingham Hip Resurfacing is an exciting re-invention of technology, said
Philip Schmitt, D.O., of DMC Huron Valley-Sinai Hospital. "Americans love new
technology and at Huron Valley we embrace it for treating our patients. Adding
Twitter as another teaching aid benefits everyone."
- Loewe Custom Hobo
- Chanel 31, RUE CAMBON Chanel
- Gucci handbag
- Chloe Cyndi
- Chloe Paraty
- Chloe Paddington Wallet
- Christian Dior tote
- Mulberry
- Armani Exchange
- Dolce
Saturday, November 28. 2009
Dr. Schmitt Completes First Live Tweet of BHR
Posted by Patricia Walter in Articles 2009, BHR, Doctors, General Information at 11:00 | Comments (0) | Trackbacks (0)
Friday, November 13. 2009
DePuy Ortho to shutter British plant, lay off 280 workers
DePuy Ortho to shutter British plant, lay off 280 workers
November 12, 2009
The orthopedics giant plans to stop making some of its older hip replacement products at its factory in Leeds, England, as sales slide in favor of its newer offerings.
DePuy Orthopaedics plans to shutter its manufacturing operations at a facility in Leeds, England, after sales declines for some of its older hip replacement products.
The Warsaw, Indiana-based orthpedics giant, which is a division of Johnson & Johnson (JNJ) and has operations in Raynham, Mass., said it will phase out manufacturing at the plant, laying off 280 workers, over the course of the rest of this year and 2010.
The company is discontinuing an older line of hip replacement and resurfacing products made in Leeds and relocating the production of other products to a plant in Cork, Ireland.
Posted by Patricia Walter in HR Devices, Joint Replacement Information at 10:08 | Comments (0) | Trackbacks (0)
Monday, November 9. 2009
Wright Medical Group, Inc. Receives FDA Approval to Market Conserve Plus Total Hip Resurfacing System
ARLINGTON, Tenn.-(BUSINESS WIRE) - Nov. 9, 2009 - Wright Medical Group, Inc. (NASDAQ: WMGI), a global orthopaedic medical device company, announced today that the United States Food and Drug Administration (FDA) has given approval to the Company to market its original CONSERVE® Plus Total Hip Resurfacing System. Now available in the United States, this innovative total surface arthroplasty system provides surgeons and their patients a bone-conserving alternative to traditional total hip replacement.
The approval permits Wright to market CONSERVE® Plus in the original femoral and acetabular component configuration specified in its PreMarket Approval (PMA) application and enables the Company to initiate efforts to introduce additional enhancements to the system which are currently only available outside of the United States. The Company intends to incorporate these innovative future product options into the CONSERVE® Plus System's femoral and acetabular component offerings via the PMA Supplement pathway.
Hip resurfacing may be ideal for young, active patients in need of surgical treatment for chronic pain. The CONSERVE® Plus system is designed to offer pain relief and restoration of function while retaining as much healthy bone as possible and preserving future surgery options, including a primary total hip replacement.
The approval follows a successful clinical trial involving more than 1,300 patients, including those enrolled under Continued Access protocols, providing patient data of CONSERVE® Plus clinical data in postoperative periods of up to eight years in length. Wright will commence surgeon training in the first phase of its U.S. introduction. The training is expected to begin immediately upon approval.
"Hip resurfacing represents a valuable alternative to younger, more active patients who desire a hip reconstruction that more anatomically mimics the natural hip," commented Patrick Fisher, Sr. Director of Marketing for Wright's hip franchise. "We have learned that this is an excellent option for patients who meet the criteria for hip resurfacing, and these individuals tend to be very enthusiastic and outspoken about their positive results."
About Wright
Wright Medical Group, Inc. is a global orthopaedic medical device company specializing in the design, manufacture and marketing of reconstructive joint devices and biologics. The Company has been in business for more than 50 years and markets its products in over 60 countries worldwide. For more information about Wright Medical, visit our website at www.wmt.com
